SCHEMBL214660

SCHEMBL214660

Cc1cc(NC(=O)c2c(C(N)=O)ncn2-c2cc(Br)ccc2C)[nH]n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIK1 P57059 2/20 0.33
SIK2 Q9H0K1 2/20 0.33
SIK3 Q9Y2K2 2/20 0.33
EPHB3 P54753 1/20 0.32
JAK2 O60674 3/20 0.32
GABRG2 P18507 4/20 0.32
GABRB3 P28472 4/20 0.32
GABRA5 P31644 4/20 0.32
GABRA1 P14867 1/20 0.32
GABRA3 P34903 1/20 0.32
GABRA2 P47869 1/20 0.32
GABRA6 Q16445 1/20 0.32
HCAR1 Q9BXC0 1/20 0.31
CCNA2 P20248 1/20 0.31
CDK2 P24941 1/20 0.31
CCNA1 P78396 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL215407 0.86 MTOR (0.38) SIK1SIK2SIK3GABRG2GABRB3
SCHEMBL214864 0.84 JAK2 (0.32) JAK2GABRG2GABRB3GABRA5GABRA1
SCHEMBL215228 0.82 SCN9A (0.44) JAK2KDM4EMEN1KMT2ARXFP1
SCHEMBL215824 0.82 RAB9A (0.41) KDM4EMEN1KMT2ARXFP1CTDSP1
SCHEMBL213975 0.82 KMT2A (0.42) KDM4EMEN1KMT2ARXFP1TP53
SCHEMBL213991 0.82 GABRG2 (0.31) SIK1SIK2SIK3JAK2GABRG2
SCHEMBL214878 0.81 MAPK8 (0.41) KDM4EHPGDTP53MAPT
SCHEMBL214574 0.80 RAB9A (0.41) KDM4EMEN1KMT2ARXFP1TP53
SCHEMBL215860 0.80 MEN1 (0.38) MEN1KMT2ARXFP1TP53RAB9A
SCHEMBL213884 0.80 HCAR1 (0.33) SIK1SIK2SIK3GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2061768-A2 IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS Exelixis, Inc. (US) 2009-05-27 EP disclosed
WO-2008042282-A2 IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS EXELIXIS, INC. (US) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 SIK1 865/4885SIK2 200/4885SIK3 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.